Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors

An enantiomerically pure compound of formula 1naznačeno wherein: Y is N or CR12R1; is selected from hydrogen, halogen, C6-12 aryl, 5-12 membered heteroaryl (wherein heteroaryl represents furan, thiophene, pyrrole, pyrroline, pyrrolidine, dioxolane, oxazole, thiazole imidazole, imidazoline, imidazolidine, pyrazole, pyrazoline, pyrazolidine, isoxazole, isothiazole, oxadiazole, triazole, thiadiazole, pyran, pyridine, piperidine, dioxane, morpholine, dithiane, thiomorpholine, pyridazine, pyrimidine, pyrazine, piperazine, triazine, trithiane, or azetidine), C3-12 cycloalkyl, 3-12 membered heteroalicyclic, -O (CR6R7) nR4, -C (O) R4, -C (O) OR 4, -CN, -NO 2, -S (O) mR4, -SO2NR4R5 , -C (O) NR4R5, -NR4C (O) R5, -C (= NR6) NR4R5, C1-6 alkyl, C2-8 alkenyl, and C2-8 alkynyl; and each hydrogen in R1 is optionally substituted by one or more R3 groups; R2 is hydrogen; each R 3 is independently halogen, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C3-12 cycloalkyl, C6-12 aryl, 3-12 membered heteroalicyclic, 5-12 membered heteroaryl, -S ( O) mR4, -SO2NR4R5, -S (O) 2OR4, -NO2, -NR4R5, - (CR6R7) n OR 4, -CN, -C (O) R4, -OC (O) R4, -O (CR6R7) nR4, -NR 4 C (O) R5, - (CR6R7) nC (O) OR4, - (CR6R7) n OR 4, - (CR6R7) nC (O) NR4R5, - (CR6R7) nNCR4R5, -C (= NR6) NR4R5, -NR4C ( O) NR5R6, -NR 4 s (O) p R 5 or -C (O) NR4R5, each hydrogen in R3 is optionally substituted by R8, and R3 groups on adjacent atoms may be combined ĐỨC C6-12 aryl, 5-12 membered heteroaryl, C 3-12 cycloalkyl or 3-12 membered heteroalicyclic group; each R4, R5, R6 and R7 is independently hydrogen, halogen, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C3-12 cycloalkyl, C6-12 aryl, , 3-12 membered heteroalicyclic, 5-12 membered heteroaryl; or any two of R4 and R5, R6 and R7 bound to the same nitrogen atom may, together with the nitrogen to which they are attached, to be combined to form a 3 to 12 membered heteroalicyclic or 5-12 membered heteroaryl group optionally containing 1 to 3 additional heteroatoms selected from N, O, and S; or any two of R4, R5, R6 and R7 bound to the carbon atom may be combined to form a C3-12 cycloalkyl, C6-12 aryl, 3-12 membered heteroalicyclic or 5-12 membered heteroaryl group; and each hydrogen in R4, R5, R6 and R7 is optionally substituted by R 8; each R 8 is independently halogen, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C3-12 cycloalkyl, C6-12aril, 3-12 and Member States heteroalicyclic, 5-12 membered heteroaryl, -NH2, -CN, -OH, -O-C1-12 alkyl, -O- (CH 2) n C 3-12 cycloalkyl, -O- (CH 2) n C 6-12 aryl, -O - (CH2) n (3-12 membered heteroalicyclic) or -O- (CH2) n (5-12 membered heteroaryl); and each hydrogen in R 8 is optionally substituted with R11; each R 11 is independently halogen, C1-12 alkyl, C1-12 alkoxy, C3-12 cycloalkyl, C6-12 aryl, 3-12 membered heteroalicyclic, 5-12 membered heteroaryl, -O-C1-12 alkyl, -O- ( CH2) n C 3-12 cycloalkyl, -O- (CH 2) n C 6-12 aryl, -O- (CH2) n (3-12 membered heteroalicyclic), -O- (C